PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21838784-0	2012	CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.	montelukast	62-73	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6	
21838784-3	2012	Our aim was to study the effects of selective CYP2C8 and CYP3A4 inhibitors on the pharmacokinetics of montelukast.	montelukast	102-113	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	46-52	
21838784-5	2012	Plasma concentrations of montelukast, gemfibrozil, itraconazole and their metabolites were measured up to 72 h. RESULTS: The CYP2C8 inhibitor gemfibrozil increased the AUC(0, ) of montelukast 4.3-fold and its t(1/2) 2.1-fold (P < 0.001).	montelukast	25-36	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	125-131	
21838784-5	2012	Plasma concentrations of montelukast, gemfibrozil, itraconazole and their metabolites were measured up to 72 h. RESULTS: The CYP2C8 inhibitor gemfibrozil increased the AUC(0, ) of montelukast 4.3-fold and its t(1/2) 2.1-fold (P < 0.001).	montelukast	180-191	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	125-131	
21838784-9	2012	CONCLUSIONS: CYP2C8 is the dominant enzyme in the biotransformation of montelukast in humans, accounting for about 80% of its metabolism.	montelukast	71-82	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	13-19	
21838784-11	2012	Montelukast may serve as a safe and useful CYP2C8 probe drug.	montelukast	0-11	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	43-49